(Q48243158)

9 February 2018

title

Variable dose naltrexone-induced hypothalamic-pituitary-adrenal stimulation in abstinent alcoholics: a preliminary study (English)

1 reference

9 February 2018

0 references

Farren CK

1

1 reference

9 February 2018

O'Malley S

2

1 reference

9 February 2018

Grebski G

3

1 reference

9 February 2018

Maniar S

4

1 reference

9 February 2018

Porter M

5

1 reference

9 February 2018

Kreek MJ

6

1 reference

9 February 2018

publication date

1 March 1999

1 reference

9 February 2018

Alcoholism: Clinical and Experimental Research

published in

1 reference

9 February 2018

volume

23

1 reference

9 February 2018

issue

3

1 reference

9 February 2018

page(s)

502-508

1 reference

9 February 2018

Development and initial validation of a measure of drinking urges in abstinent alcoholics

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.1999.TB04144.X

Effects of naloxone, morphine and methionine enkephalin on serum prolactin, luteinizing hormone, follicle stimulating hormone, thyroid stimulating hormone and growth hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.1999.TB04144.X

High-dose naloxone infusions in normals. Dose-dependent behavioral, hormonal, and physiological responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.1999.TB04144.X

The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.1999.TB04144.X

Aversive effects of naltrexone in subjects not dependent on opiates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.1999.TB04144.X

Cortisol and beta-endorphin response in alcoholics and alcohol abusers following a high naloxone dosage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.1999.TB04144.X

Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.1999.TB04144.X

Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.1999.TB04144.X

Corticotrophin-releasing factor, vasopressin and pro-opiomelanocortin mRNA responses to stress and opiates in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.1999.TB04144.X

Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.1999.TB04144.X

Effects of naloxone on diurnal rhythms in mood and endocrine function: a dose-response study in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.1999.TB04144.X

Effects of naltrexone on mood and neuroendocrine function in normal adult males

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.1999.TB04144.X

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.1999.TB04144.X

Naltrexone-induced dysphoria in former opioid addicts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1530-0277.1999.TB04144.X

10.1111/J.1530-0277.1999.TB04144.X

21 January 2018

Identifiers

DOI

1 reference

9 February 2018

release_4bzv2777ffag3e2yosf7bxndta

Fatcat ID

0 references

1 reference

9 February 2018